Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

6 - Uterine fibroids and heavy menstrual bleeding

References

1. ButtramVC Jr, ReiterRC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36:433–45.
2. FraserIS, McGarronG, MarkhamR, RestaT, WattsA. Measured menstrual blood loss in women with pelvic disease or coagulation disorder. Obstet Gynecol 1986;68:630–3.
3. SulaimanS, KhaundA, McMillanN, MossJ, LumsdenMA. Uterine fibroids – do size and location determine menstrual bloodloss?Eur J Obstet Gynecol Reprod Biol 2004;115:85–9.
4. SinclairDC, MastroyannisA, TaylorHS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3. J Clin Endocrinol Metab 2011;96:412–21.
5. MaybinJA, CritchleyHO, JabbourHN. Inflammatory pathways in endometrial disorders. Mol Cell Endocrinol 2011;335:42–51.
6. KangJL, WangDY, WangXX, YuJ. Up-regulation of apoptosis by gonadotrophin-releasing hormone agonist in cultures of endometrial cells from women with symptomatic myomas. Hum Reprod 2010;25:2270–5.
7. KlatskyPC, TranND, CaugheyAB, FujimotoVY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008;198:357–66.
8. LumsdenMA, WestCP, ThomasE, et al. Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. BrJ Obstet Gynaecol 1994;101:438–42.
9. ZimmermannA, BernuitD, GerlingerC, SchaefersM, GeppertK. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health 2012;12:6.
10. MareshM, MetcalfeMA, McPhersonK, et al. The VALUE national hysterectomy study: description of the patients and their surgery. BJOG 2002;109:302–12.
11. McPhersonK, MetcalfeMA, HerbertA, et al. Severe complications of hysterectomy: the VALUE study. BJOG 2004;111:688–94.
12. LumsdenMA. Modern management of fibroids. Obstet Gynaecol Reprod Med 2010;20:82–6.
13. WenKC, SungMD, ChaoKC, LeeWL, LiuWM, WangPH. A prospective short-term evaluation of uterine leiomyomas treated by myomectomy through conventional laparotomy or ultraminilaparotomy. Fertil Steril 2008;90:2361–6.
14. van der KooijSM, BipatS, HehenkampWJ, AnkurnWM, ReckersJA. Uterine artery embolization versus surgery in the treatment of symptomatic fibroids: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;205:317.e1–18.
15. EdwardsRD, MossJG, LumsdenMA, et al.; Committee of the Randomized Trial of Embolization versus Surgical Treatment of Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;356:360–70.
16. van der KooijSM, HehenkampWJ, VolkersNA, BirnieE, AnkumWA, ReekersJA. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial. Am J Obstet Gynecol 2010;203:105.e1–13.
17. MossJG, CooperKG, KhaundA, et al. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG 2011;118:936–44.
18. KhaundA, MossJG, McMillanN, LumsdenMA. Evaluation of the effect of uterine artery embolisation on menstrual blood loss and uterine volume. BJOG 2004;111:700–5.
19. HirstA, DuttonS, WuO, et al. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study. Health Technol Assess 2008;12:1–248, iii.
20. DuttonS, HirstA, McPhersonK, NicholsonT, MareshM. A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG 2007;114:1340–51.
21. RashidS, KhaundA, MurrayLS, et al. The effects of uterine artery embolisation and surgical treatment on ovarian function in woman with uterine fibroids. BJOG 2010;117:985–9.
22. BouchardP, Chabbert-BuffetN, FauserBC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:1175–89.
23. WilkinsJ, ChwaliszK, HanC, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol & Metabol 2008;93:4664–71.
24. DonnezJ, TatarchukTF, BouchardP, et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409–20.
25. DonnezJ, TomaszewskiJ, VázquezF, et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32.
26. HudsonSB, StewartEA. Magnetic resonance-guided focused ultrasound surgery. Clin Obstet Gynecol 2008;51:159–66.
27. GornyKR, WoodrumDA, BrownDL, et al. Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients. J Vasc Interv Radiol 2011;22:857–64.
28. BouwsmaEV, GornyKR, HesleyGK, JensenJR, PetersonLG, StewartEA. Magnetic resonance-guided focused ultrasound surgery for leiomyoma-associated infertility. Fertil Steril 2011;96:e9–e12.
29. BouwsmaEV, HesleyGK, WoodrumDA, et al. Comparing focused ultrasound and uterine artery embolization for uterine fibroids-rationale and design of the Fibroid Interventions: reducing symptoms today and tomorrow (FIRSTT) trial. Fertil Steril 2011;96:704–10.